Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wiström, J.
Right arrow Articles by Englund, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiström, J.
Right arrow Articles by Englund, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 20, 563-574
© 1987 The British Society for Antimicrobial Chemotherapy

research-article

Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea

Johan Wiströma,, S. Ragnar Norrbya, Lars. G. Burmanb, Rolf Lundholmc, Birgit Jellhedend and Gunnar Englundd

aDepartment of Infectious Diseases, University of Umeå, Umeå Stockholm bThe National Bacteriological Laboratory Stockholm cDepartment of Clinical Bacteriology, University of Umeå, Umeå Södertälje, Sweden dAstra Alab AB Södertälje, Sweden

accepted 25 May 1987

Correspondence to: Johan Wiström, M.D., Department of Infectious Diseases, University of Umeå, Umeå University Hospital, S-90185 Umeå Sweden

In a randomized, double blind study, 127 subjects travelling to countries outside Northern Europe were given norfloxacin 200 mg or placebo bid as prophylaxis against diarrhoea. Fifty-six subjects randomized to norfloxacin and 59 to placebo fulfilled criteria for evaluation of efficacy and of those, respectively six and 20 (P = 0.0006) developed diarrhoea. The mean duration of symptoms in the placebo group was 3.6 days, while all subjects on norfloxacin had symptoms for one day only. In travellers to Mediterranean Europe or the Canary Islands, no significant differences were seen between norfloxacin and placebo. Among subjects going to Africa, Asia or Latin America, 4/32 subjects on norfloxacin and 16/30 on placebo developed diarrhoea (P = 0.0004). Adverse effects were few and mild. Faeces for aerobic cultures was obtained before travelling and three weeks and then three months post-treatment. Treatment with norfloxacin resulted in a significant reduction of samples yielding aerobic Gram-negative rods but did not affect enterococci. In the placebo group, Gram-negative organisms other than Escherichia coli were increased on return to Sweden and the subjects frequently acquired Gram-negative organisms resistant to antibiotics. In none of the groups was there a tendency towards increased norfloxacin resistance. Biotyping of E. coli showed that in both groups the subjects changed their E. coli strains frequently during and after travelling. This trial showed that norfloxacin is a safe and effective prophylactic agent with no adverse effect on bacterial flora, but that its use should be restricted to travellers to non-European countries.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DTBHome page
What to do about traveller's diarrhoea
DTB, May 1, 2002; 40(5): 36 - 38.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. L. DuPont and C. D. Ericsson
Prevention and Treatment of Traveler's Diarrhea
N. Engl. J. Med., June 24, 1993; 328(25): 1821 - 1827.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.